Adecatumumab
EpCAM | |
|---|---|
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6552H10080N1740O2052S46 |
| Molar mass | 147533.60 g·mol−1 |
  (what is this?) (verify) | |
Adecatumumab (MT201) is a recombinant
EpCAM - CD326), with the intent to trigger antibody-dependent cellular cytotoxicity. It was developed by Micromet Inc, which was acquired by Amgen.[1]
Adecatumumab has been used in clinical studies of treatment in colorectal, prostate[2] and breast cancers.[3] Phase II results were published in 2010.[4]
References
- ^ "Adecatumumab - Amgen/Merck Serono". Adis Insight. Springer Nature Switzerland AG.
- PMID 16930989.
- PMID 15655555.
- PMID 19633042.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |